Search research articles
Contact Us
Filters
Showing results (121-130 of 191) with videos related to
Page
of 20
Sort By:
Prostate Cancer and Prostatic Diseases
|
February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Contemporary Clinical Trials
|
November 3, 2021
Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer
Laurence Klotz, Gerald Andriole, Hannes Cash, et al.
World Journal of Urology
|
January 31, 2018
Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement
Neal Shore, Ronald Tutrone, Mitchell Efros, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 23, 2026
An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy
Luke T Nordquist, Jack R Andrews, Phillip H Kuo, et al.
Prostate Cancer and Prostatic Diseases
|
June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
Quoc-Dien Trinh, Daniel J George, Neal Shore, et al.
Targeted Oncology
|
October 2, 2019
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
Neal Shore, Christian Zurth, Robert Fricke, et al.
The New England Journal of Medicine
|
September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi, Neal Shore, Teuvo L Tammela, et al.
Targeted Oncology
|
April 3, 2025
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial
Jose De La Cerda, Laurence Belkoff, Kevin D Courtney, et al.
Prostate Cancer and Prostatic Diseases
|
April 14, 2019
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Eda K Holl, Megan A McNamara, Patrick Healy, et al.
European Urology Oncology
|
November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
Fred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 191) with videos related to
Sort By:
Page
of 20
Prostate Cancer and Prostatic Diseases
|
February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Contemporary Clinical Trials
|
November 3, 2021
Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer
Laurence Klotz, Gerald Andriole, Hannes Cash, et al.
World Journal of Urology
|
January 31, 2018
Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement
Neal Shore, Ronald Tutrone, Mitchell Efros, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 23, 2026
An intra-patient contemporaneous comparison of <sup>18</sup>F-piflufolastat and <sup>18</sup>F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy
Luke T Nordquist, Jack R Andrews, Phillip H Kuo, et al.
Prostate Cancer and Prostatic Diseases
|
June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
Quoc-Dien Trinh, Daniel J George, Neal Shore, et al.
Targeted Oncology
|
October 2, 2019
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
Neal Shore, Christian Zurth, Robert Fricke, et al.
The New England Journal of Medicine
|
September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi, Neal Shore, Teuvo L Tammela, et al.
Targeted Oncology
|
April 3, 2025
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial
Jose De La Cerda, Laurence Belkoff, Kevin D Courtney, et al.
Prostate Cancer and Prostatic Diseases
|
April 14, 2019
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Eda K Holl, Megan A McNamara, Patrick Healy, et al.
European Urology Oncology
|
November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
Fred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Page
of 20